Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
1D3HMCys TCR-modified T cells
- Development stage
- Discontinued
- Lead developer
- Vrije University Medical Center
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
1D3HMCys TCR-modified T cells are autologous peripheral blood T cells engineered to express a murinized, gene-optimized T-cell receptor (TCR) targeting the HLA-A*02:01-restricted MART-1(26-35) epitope, a melanoma antigen recognized by T cells. The 1D3HMCys TCR contains murine constant regions to improve expression and reduce mispairing, and incorporates an extra cysteine for enhanced stability, plus a P2A peptide linker for equal expression of both chains. These T cells are expanded ex vivo with IL-7 and IL-15 to generate products with a less-differentiated, memory stem/central memory phenotype. Developed as a form of adoptive cell therapy for metastatic melanoma, the therapy demonstrated in clinical trials both feasibility and potent antitumor activity, but was associated with dose-dependent, on-target off-tumor toxicities, including dermatitis, uveitis, hearing loss, and cytokine release syndrome, leading to early termination of trials[1][2][3].
- Other names
- MART-1(26-35) TCR-modified T cellsmurinized MART-1-specific TCR-modified T cells
02
Targets
MART-1/HLA-A*02:01 (Melanoma-associated antigen (Melanoma antigen recognized by T cells 1, Melanocyte protein PMEL, Tyrosinase) peptide-HLA-A*02:01 complex)
Beyond the preview
Go deeper on 1D3HMCys TCR-modified T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 1D3HMCys TCR-modified T cells.